A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3). - Wikidata - wikimedia - TriplyDB

A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3).

A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3).

http://www.wikidata.org/entity/Q36494733

about

Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research Perspectives for therapeutic HPV vaccine development Spontaneous and Vaccine-Induced Clearance of Mus Musculus Papillomavirus 1 Infection Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNγ Intravaginal HPV DNA vaccination with electroporation induces local CD8+ T-cell immune responses and antitumor effects against cervicovaginal tumors.Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated disease Incisal margin condition after LEEP for cervical intraepithelial neoplasia patients and prognosis.Histone deacetylase inhibitor AR-42 enhances E7-specific CD8⁺ T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination.Moving forward with human papillomavirus immunotherapies.Cervical Cancer: Development of Targeted Therapies Beyond Molecular Pathogenesis.DNA Vaccine Encoding HPV16 Oncogenes E6 and E7 Induces Potent Cell-mediated and Humoral Immunity Which Protects in Tumor Challenge and Drives E7-expressing Skin Graft Rejection Immunologic responses to a novel DNA vaccine targeting human papillomavirus-11 E6E7.Coinjection of IL2 DNA enhances E7-specific antitumor immunity elicited by intravaginal therapeutic HPV DNA vaccination with electroporation.The current state of therapeutic and T cell-based vaccines against human papillomaviruses.Attitudes towards Human Papilloma Virus Vaccination in the Latin American Andean Region.Therapeutic vaccines for high-risk HPV-associated diseases.Targeted immunotherapy of high-grade cervical intra-epithelial neoplasia: Expectations from clinical trials.Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases.Targeting Head and Neck Cancer by Vaccination.Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model.Trial watch: DNA-based vaccines for oncological indications Emerging human papillomavirus vaccines

P2860

Q26744094-00970F3C-37B9-470B-ADD6-19EE26B721F7 Q28069272-2971AD63-9ACD-4C0C-91D2-483F5C9C433A Q33907700-7870857D-7F2E-4ACC-AF7E-D636A88B3978 Q34438411-A85FE9E3-63B8-4BBF-B1B2-6CDD78A302C5 Q35812239-50B74652-F5B8-40B7-AE63-0E2B627D0A51 Q36616505-E69B907E-D85C-4DAF-88D5-9854BFF2E025 Q37107984-7B88D8D1-CBFF-4B45-9CBD-E5B3D62C0BE6 Q37198835-F6B3E391-F4BA-4F02-A34E-BEEE60376599 Q37473299-8CDCAC07-9709-4CBA-9335-C25BAD66E5EA Q37579334-3ACDEB06-2594-46D0-98B5-C125EF2679E3 Q37626311-04B60A60-7EF3-4248-B4FE-247730FB2DD4 Q38697123-7D7DA38F-AF10-4FA8-8FC3-A9A37A2AA20E Q38792909-61E29747-3B5E-4703-BBBA-EF92EDDDE1A2 Q39033576-B4EF527D-7ACD-484E-9229-B6F5B8FDA4BC Q40051093-9C866C2B-21A5-4CDE-89AB-CAD83FA6966F Q47255618-BB2EA5BD-3C41-411C-ADA6-EA860CBE64CC Q50052586-59EA5348-A4EB-4A6F-AEA7-E4411B6C4EE7 Q50115667-E362E177-E856-4D06-9C2C-765204B65A4E Q54217605-2B8B16EC-D33C-4963-BB67-AD07C717A830 Q55086081-23433512-D20E-4BE1-B0A7-FDBCC94EBFC3 Q56893452-F3E0FEA3-1108-4276-B3A7-490965A7B258 Q56967486-1F021971-11AF-4D4E-8CB2-38449F126B98

P2860

A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3).

http://www.wikidata.org/entity/Q36494733

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

A pilot study of pNGVL4a-CRT/E ...... helial neoplasia 2/3 (CIN2/3).

@ast

A pilot study of pNGVL4a-CRT/E ...... helial neoplasia 2/3 (CIN2/3).

@en

type

label

A pilot study of pNGVL4a-CRT/E ...... helial neoplasia 2/3 (CIN2/3).

@ast

A pilot study of pNGVL4a-CRT/E ...... helial neoplasia 2/3 (CIN2/3).

@en

prefLabel

A pilot study of pNGVL4a-CRT/E ...... helial neoplasia 2/3 (CIN2/3).

@ast

A pilot study of pNGVL4a-CRT/E ...... helial neoplasia 2/3 (CIN2/3).

@en

P1433

Q36494733-04D1067B-75C5-4287-90D6-57E53BDC0BE9

P1476

Q36494733-02559228-FDC0-47B9-9B69-A567CCCD34C8

P2093

Q36494733-1716E324-D099-44D4-B5F3-4B2E083E62CB

Q36494733-20A4E951-0CCA-41DC-981A-5302872E9F8F

Q36494733-2A0CA587-7664-4D47-8CF2-72D0D41D7841

Q36494733-2E80CAD9-0B9D-4DDC-AD22-CC2A8D867E48

Q36494733-46DB9005-2F8D-4BFA-B647-AC8AB3D8F56E

Q36494733-4E5080A0-60C3-443A-B31A-08ACF6A530E5

Q36494733-5B73560D-8628-4B90-9808-E5CE3C587886

Q36494733-6206512F-66CB-463B-B780-915B7DF5F33B

Q36494733-660BFE98-0BA5-401C-82E5-8B3FA9E7B35F

Q36494733-8F01D066-92AB-4315-8744-A29625CD8AAF

P2860

Q36494733-01D8704B-5DE5-4169-B969-74A6365AB4F1

Q36494733-054BA356-9A9E-4E6E-B1BE-0F2930A7D118

Q36494733-066E7F9D-C40B-429F-BDA3-24E887EFA224

Q36494733-09372FDF-83B6-4925-AC60-4F073A21F22E

Q36494733-0B8BDB96-FE83-4806-9CA2-AFB0AE7187D7

Q36494733-13764ABA-6D84-4993-9499-2FA58A7D06EA

Q36494733-1626C665-DAD0-4993-9E17-379895E142C6

Q36494733-204EB54C-6699-48CC-BF5D-72D8320DC03A

Q36494733-24075033-5243-4EF2-8108-07F8CEE7385A

Q36494733-2A069B6A-F993-4764-A10F-95D30DB90DA7

P304

Q36494733-B7195509-2E51-46ED-A837-F4453043817F

P31

Q36494733-0475FAD8-BF6E-4AC2-BC00-8E51C79DE05B

P356

Q36494733-891F2018-40D6-40A5-9A60-753C0EBDE599

P407

Q36494733-9EB9A12E-4C1B-4D84-B7AF-ECE444F0571C

P433

Q36494733-C88B92E0-6D20-460D-A063-AD1389A7FF8E

P478

Q36494733-40C2DC10-1108-4E81-8608-C7518874BA0D

P577

Q36494733-5E92C0C0-2479-4A1E-9B15-684784D839D0

P698

Q36494733-7302D1D6-2279-4E5C-BC48-26A7370369DA

P932

Q36494733-CD9C62E0-57B7-4458-9813-3D0C89AFB40E

P356

J.YGYNO.2015.11.026

P1433

Gynecologic Oncology

P1476

A pilot study of pNGVL4a-CRT/E ...... helial neoplasia 2/3 (CIN2/3).

@en

P2093

Bradford E Jackson

http://www.w3.org/2001/XMLSchema#string

Chenguang Wang

http://www.w3.org/2001/XMLSchema#string

Chien-Fu Hung

http://www.w3.org/2001/XMLSchema#string

Cornelia L Trimble

http://www.w3.org/2001/XMLSchema#string

Elizabeth Sauter

http://www.w3.org/2001/XMLSchema#string

Emily A Adams

http://www.w3.org/2001/XMLSchema#string

Jean Boyer

http://www.w3.org/2001/XMLSchema#string

Lawrence S Lamb

http://www.w3.org/2001/XMLSchema#string

Michael G Conner

http://www.w3.org/2001/XMLSchema#string

Mihaela Paradis

http://www.w3.org/2001/XMLSchema#string

P2860

Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)

Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels

Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments

Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia.

A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3.

Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions.

Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination

Naturally occurring systemic immune responses to HPV antigens do not predict regression of CIN2/3

Immune surveillance in the skin: mechanisms and clinical consequences.

Control of HPV infection and related cancer through vaccination.

P304

245-252

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.YGYNO.2015.11.026

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

140

http://www.w3.org/2001/XMLSchema#string

P577

2015-11-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26616223

http://www.w3.org/2001/XMLSchema#string

P932

4724445

http://www.w3.org/2001/XMLSchema#string